TTRX catalyst calendar

Turn Therapeutics Inc.

Upcoming catalysts
2
Cash runway
18.3 months
Cash & investments
$10M
Phase 3 programs
1

Turn Therapeutics Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 13, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 18.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
November 13, 2026 est. Next quarterly earnings (projected) Earnings —
January 20, 2027 A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) Trial Milestone Phase 2/Phase 3

Track TTRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open TTRX in the tracker

Recent history

DateEventTypePhase
October 7, 2026 8-K filed: Reg FD disclosure Filing —
September 10, 2026 8-K filed: Reg FD disclosure Filing —
September 9, 2026 8-K filed: Reg FD disclosure Filing —
August 17, 2026 8-K filed: Reg FD disclosure Filing —
August 12, 2026 Quarterly results filed (8-K) Earnings —
July 28, 2026 8-K filed: Reg FD disclosure Filing —
July 7, 2026 8-K filed: Reg FD disclosure Filing —
June 3, 2026 8-K filed: Reg FD disclosure Filing —
June 1, 2026 8-K filed: Reg FD disclosure Filing —
May 27, 2026 8-K filed: Reg FD disclosure Filing —
May 19, 2026 8-K filed: Reg FD disclosure Filing —
May 18, 2026 8-K filed: Reg FD disclosure Filing —
May 11, 2026 Quarterly results filed (8-K) Earnings —
March 31, 2026 Quarterly results filed (8-K) Earnings —
March 24, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
February 17, 2026 8-K filed: Reg FD disclosure Filing —
February 9, 2026 8-K filed: Reg FD disclosure Filing —
January 12, 2026 8-K filed: Reg FD disclosure Filing —
January 7, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
November 13, 2025 Quarterly results filed (8-K) Earnings —
November 12, 2025 8-K filed: Reg FD disclosure Filing —
November 4, 2025 8-K filed: Reg FD disclosure Filing —
October 30, 2025 8-K filed: Reg FD disclosure Filing —
October 28, 2025 8-K filed: Material agreement Corporate —
October 22, 2025 8-K filed: Reg FD disclosure Filing —
October 2, 2025 8-K filed: Material agreement, Leadership change Corporate —
May 30, 2021 Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19. Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.